

Indian pharma clocks 8.9% growth in June 2013: IMS

24 July 2013 | News | By BioSpectrum Bureau



New Delhi: The IMS Health Total Sales Audit (TSA) has released a report stating that the Indian pharmaceutical market has clocked a growth of 8.9 percent during the month of June 2013.

The report pointed out that market had remained fairly static for the month of June 2013 as compared to the previous month. Further, it specified that the strong onset of monsoons across the country, which saw acute therapies like respiratory, gastro-intestinals, anti-infectives and pain soar, was offset to some extent by the subdued reaction from the trade to DPCO 2013 announcement.

A survey of stockists conducted by IMS Health revealed that 40 percent of respondents had incomplete knowledge about DPCO 2013 and its implication. The report said that 'clarity is still an issue particularly in North India, followed to some extent in East India.'

While GlaxoSmithKline (GSK) climbed up two ranks in June as compared to the previous month, Ranbaxy has dropped two ranks down, ranks of other corporations remained unchanged. For June, local companies have grown almost twice by 10.2 percent as compared to MNCs at 5.5 percent.

During June 2013, Respiratory segment has overtaken anti-diabetics as the fastest growing therapy with growth of 22.8 percent followed by anti-diabetic by 15.1 percent and gastro-intestinal at 9.8 percent.

Led by the strong onset of monsoons all across the country, acute therapies grew almost at par with the chronic segment. Acute therapies contributed 71 percent to total with growth of 8.8 percent and chronic therapies contributed 29 percent with growth of nine percent.

The IMS market Prognosis report forecasted that the market will recover over the next few months, as issues around market regulations clear out and register a FY 2013 growth between 11-13 percent.

The pharmaceutical market for the period MAT June 2013, improved by 10 percent. Abbott remained on top position followed by Cipla, Sun Pharmaceutical, GlaxoSmithKline and Zydus Cadila respectively.